Statements (23)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:biotechnology
|
gptkbp:CEO |
Sijmen de Vries
|
gptkbp:country |
gptkb:Netherlands
|
gptkbp:focus |
rare diseases
|
gptkbp:founded |
1988
|
gptkbp:founder |
Bruno Giannetti
|
gptkbp:headquarters_location |
gptkb:Leiden
|
https://www.w3.org/2000/01/rdf-schema#label |
Pharming Group NV
|
gptkbp:industry |
gptkb:biotechnology
|
gptkbp:listedOn |
gptkb:Euronext_Amsterdam
|
gptkbp:main_therapeutic_area |
gptkb:hereditary_hemorrhagic_telangiectasia
|
gptkbp:market |
global
|
gptkbp:notableProduct |
recombinant human C1 esterase inhibitor
|
gptkbp:numberOfEmployees |
~300
|
gptkbp:product |
gptkb:Ruconest
|
gptkbp:publiclyTraded |
yes
|
gptkbp:regulates |
gptkb:FDA
gptkb:EMA |
gptkbp:stockExchange |
gptkb:Euronext_Amsterdam
|
gptkbp:stockSymbol |
PHARM
|
gptkbp:website |
https://www.pharming.com/
|
gptkbp:bfsParent |
gptkb:Ruconest
|
gptkbp:bfsLayer |
8
|